Vasculitis & polymyalgia rheumatica
The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain
Authors' conclusion
The combination of avacopan with standard immunosuppressive therapy presents a good safety profile and provides added value by contributing to the control of AAV activity, increase GFR and removal of steroids.
Study context
- Population
- Patients with ANCA-associated vasculitis (AAV) in Spain (Early Access program); median age 56 years, 41.4% male, 72.4% ANCA MPO positive, kidney involvement 79.31%29 avacopan patients analysed
- Exposure
- Avacopan with standard immunosuppressive therapy vs historical cohort treated without avacopan
- Avacopann = 29
- Outcome
- Remission rate
- Follow-up
- Mean 456.8 (±181.7) days
Methodological detailsreal-world, Early Access program, historical control cohort
- Real-world
- Early Access program
- Historical control cohort
Main finding
As reported in the abstract
Remission rate with avacopan
86.2%
Mean follow-up, days (±SD)
456.8
±181.7
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Cumulative prednisone dose, avacopan vs historical controls · 6 and 12 monthsAvacopan vs Historical controls · significantly lower with avacopan at 6 months | P-values of 0.02 |
| Cumulative prednisone dose, avacopan vs historical controls · 6 and 12 monthsAvacopan vs Historical controls · significantly lower with avacopan at 12 months | <0.01 |
Estimated glomerular filtration rate (eGFR) with avacopan, ml/min · 12 months after diagnosis
- eGFR increased from baseline, ml/min
- 23.2 (11.2)
- eGFR at 12 months, ml/min
- 38.38 (18.55)
GFR evolution at 1 year and relapse incidence, avacopan vs historical controls
- Similar in both groups
Safety
- Infections — Avacopan
- 13 events
- Adverse events related to avacopan
- 2 · events
Original publication
The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology (Oxford). Published 1 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →